Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Winter

Showing results (181-190 of 252) with videos related to

Pageof 26
Sort By:
British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
Vaccine|June 16, 2009
Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasiaD Pathirana, P Hillemanns, K-U Petry, et al.
Blood|February 2, 2006
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyJane N Winter, Edie A Weller, Sandra J Horning, et al.
Blood Advances|July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and EfficacyOluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Blood Advances|September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphomaPamela B Allen, Xinyan Lu, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cellsJ N Winter, H M Lazarus, A Rademaker, et al.
Pageof 26

Showing results (181-190 of 252) with videos related to

Sort By:
Pageof 26
British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
Vaccine|June 16, 2009
Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasiaD Pathirana, P Hillemanns, K-U Petry, et al.
Blood|February 2, 2006
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyJane N Winter, Edie A Weller, Sandra J Horning, et al.
Blood Advances|July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and EfficacyOluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Blood Advances|September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphomaPamela B Allen, Xinyan Lu, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cellsJ N Winter, H M Lazarus, A Rademaker, et al.
Pageof 26